Phase 2 Thyroid Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with thyroid cancer, confirmed by a pathology report reviewed at the National Institutes of Health.
- People who have had their entire thyroid removed (and possibly nearby lymph nodes), and whose cancer has come back or spread — either confirmed by imaging scans (such as ultrasound, CT, or MRI), or strongly suspected based on high-risk features such as a large tumour, cancer that grew beyond the thyroid, certain aggressive cancer types, positive surgical margins, bulky lymph nodes in the neck, or rising levels of a protein called thyroglobulin (or related antibodies) in the blood.
- People who have never had radioactive iodine (RAI) treatment, or who need repeated RAI treatment for advanced or spreading disease, or who have previously received certain targeted drug treatments (dabrafenib, vemurafenib, or selumetinib) for at least 4 weeks that may help the cancer respond to RAI again.
- People who have had a brain and spine scan (CT or MRI with contrast dye) to check for cancer spread to those areas.
- People aged 18 years or older.
- People whose 24-hour urine iodine level is at or below 150 micrograms (confirm with trial site).
Who may not be able to join:
- People whose cancer has been shown not to absorb radioactive iodine — confirmed by negative whole-body scans after previous RAI treatments — and who have not had re-differentiation therapy.
- People with serious medical conditions that would limit safe testing or treatment, such as kidney failure, heart failure, another active cancer (other than thyroid cancer), or severe depression that could be worsened by stopping thyroid hormone.
- People who have cancer that has spread to the brain or spine, as stimulating certain hormones may cause dangerous swelling around those areas (these individuals may be assessed under a separate standard-of-care protocol).
- People who are pregnant or breastfeeding (based on self-report).
- People who are not able to give their own informed consent to participate.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Joanna Klubo-Gwiezdzinska, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phone: (301) 451-7710
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Comparison of the whole body and lesional 124I uptake within each patient prepared for imaging with human recombinant TSH (rhTSH) and thyroid hormone withdrawal (THW)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.